TherapeuticsMD
TXMD
52 hedge funds and large institutions have $20.2M invested in TherapeuticsMD in 2022 Q2 according to their latest regulatory filings, with 11 funds opening new positions, 17 increasing their positions, 18 reducing their positions, and 82 closing their positions.
0.58% less ownership
Funds ownership: 24.54% → 23.96% (-0.58%)
6% less repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 18
16% less call options, than puts
Call options by funds: $4.21M | Put options by funds: $5.02M
52% less capital invested
Capital invested by funds: $42.6M → $20.2M (-$22.3M)
58% less funds holding
Funds holding: 124 → 52 (-72)
87% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 82
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$6.54M |
| 2 |
E
Ergoteles
New York
|
+$809K |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$667K |
| 4 |
Millennium Management
New York
|
+$548K |
| 5 |
DHFB
Dixon Hubard Feinour & Brown
Roanoke,
Virginia
|
+$482K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$3.5M |
| 2 |
CWG
C WorldWide Group
Copenhagen,
Denmark
|
-$2.35M |
| 3 |
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Toronto,
Ontario, Canada
|
-$1.31M |
| 4 |
Renaissance Technologies
New York
|
-$1.2M |
| 5 |
State Street
Boston,
Massachusetts
|
-$1.1M |
TXMD Hedge Fund Activity: Q2 2022 in Review
52 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in TherapeuticsMD (TXMD) for Q2 2022, worth a combined $20.2M — down 52% from $42.6M a quarter earlier.
Sellers outnumbered buyers: 82 funds closed out of TXMD and 11 opened new positions — a net loss of 71 holders — while 18 trimmed existing stakes and 17 added.
The largest buyer was Rubric Capital Management (New York), adding an estimated $6.54M. The largest seller was BlackRock, cutting an estimated $3.5M.
- 52 institutional investors held TherapeuticsMD (TXMD) as of Q2 2022, down from 124 in Q1 2022.
- Funds reported $20.2M of TherapeuticsMD stock for Q2 2022, down 52% quarter-over-quarter.
- 11 funds opened new TherapeuticsMD positions in Q2 2022 and 82 closed out, a net change of -71 holders.
- The largest TherapeuticsMD buyer in Q2 2022 was Rubric Capital Management (New York), an estimated $6.54M added.
- The largest TherapeuticsMD seller in Q2 2022 was BlackRock, an estimated $3.5M sold.
Based on aggregated 13F filings for Q2 2022.